Clinical trial strategy was developed through research on a gene associated with treatment-resistant prostate cancer
Cleveland Clinic-developed test identifies variant of HSD3B1 gene
What's driving tumor progression is the key, says Nima Sharifi, MD
Men with the HSD3B1(1245C) variant metabolize abiraterone differently
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Researchers identify isoform that may prevent progression to advanced disease
Alteration ‘opens the floodgates’ to DHT synthesis in prostate tumors
Alteration ‘opens the floodgates’ to DHT synthesis in prostate tumors